BlackRock Inc. - CUE BIOPHARMA INC ownership

CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 77 filers reported holding CUE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.1%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of CUE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$4,896,585
-35.1%
2,128,950
+3.0%
0.00%
Q2 2023$7,541,171
+217.9%
2,066,074
+211.0%
0.00%
Q1 2023$2,372,000
+18.5%
664,426
-5.4%
0.00%
Q4 2022$2,001,217
+15.2%
702,181
-9.8%
0.00%
Q3 2022$1,737,000
-16.2%
778,708
-6.4%
0.00%
Q2 2022$2,072,000
-82.2%
831,925
-65.1%
0.00%
Q1 2022$11,622,000
-55.1%
2,381,267
+4.0%
0.00%
-100.0%
Q4 2021$25,903,000
-17.7%
2,290,269
+6.0%
0.00%0.0%
Q3 2021$31,476,000
+25.7%
2,160,458
+0.5%
0.00%0.0%
Q2 2021$25,034,000
-8.7%
2,148,798
-4.4%
0.00%0.0%
Q1 2021$27,422,000
+1.3%
2,247,704
+3.9%
0.00%0.0%
Q4 2020$27,059,000
-15.0%
2,162,978
+2.2%
0.00%0.0%
Q3 2020$31,841,000
-32.8%
2,115,645
+9.5%
0.00%
-50.0%
Q2 2020$47,349,000
+151.0%
1,931,756
+45.3%
0.00%
+100.0%
Q1 2020$18,865,000
-14.4%
1,329,428
-4.2%
0.00%0.0%
Q4 2019$22,029,000
+114.0%
1,387,669
+13.6%
0.00%
Q3 2019$10,295,000
-0.3%
1,221,270
+6.4%
0.00%
Q2 2019$10,321,000
+41.1%
1,148,126
+21.3%
0.00%
Q1 2019$7,314,000
+72.4%
946,140
+4.8%
0.00%
Q4 2018$4,243,000
-48.4%
902,906
-0.6%
0.00%
Q3 2018$8,222,000
-21.4%
908,512
+3.0%
0.00%
Q2 2018$10,461,000
+88.6%
881,959
+123.4%
0.00%
Q1 2018$5,547,000394,8270.00%
Other shareholders
CUE BIOPHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Prosight Management, LP 1,545,573$3,447,0001.85%
P.A.W. CAPITAL CORP 200,000$446,0000.67%
SANDERS MORRIS HARRIS LLC 848,048$2,020,0000.50%
Monaco Asset Management SAM 458,851$1,023,0000.39%
Bleichroeder LP 555,000$1,238,0000.26%
APOGEM CAPITAL LLC 110,614$247,0000.25%
Slate Path Capital LP 1,483,619$3,308,0000.22%
Voss Capital, LLC 200,000$446,0000.13%
Robertson Stephens Wealth Management, LLC 478,500$1,067,0000.11%
CARLSON CAPITAL L P 535,000$1,193,0000.09%
View complete list of CUE BIOPHARMA INC shareholders